Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia.

• Main Authors: Joseph A Jeffry, Shuang-Quan Yu, Parul Sikand, Arti Parihar, M Steven Evans, Louis S Premkumar
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2009-09-01
• Series: PLoS ONE
• Online Access: http://europepmc.org/articles/PMC2737142?pdf=render

Chronic pain is a major clinical problem and opiates are often the only treatment, but they cause significant problems ranging from sedation to deadly respiratory depression. Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block. Intrathecal administration of RTX to rats in the short-term inhibits nociceptive synaptic transmission, and in the long-term causes a localized, selective ablation of TRPV1-expressing central sensory nerve terminals leading to long lasting analgesia in behavioral models. Since RTX actions are selective for central sensory nerve terminals, other efferent functions of dorsal root ganglion neurons can be preserved. Preventing nociceptive transmission at the level of the spinal cord can be a useful strategy to treat chronic, debilitating and intractable pain.